Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]The Lancet Neurology: Neurology in the elderly: more trials urgently needed. Lancet Neurology 8, 969 (2009)

  • [2]A Vann: Alzheimer’s … Our new cancer? J Am Geriatr Soc 59, 2396-7 (2011)

  • [3]L M de Lau, M M Breteler: Epidemiology of Parkinson’s disease. Lancet Neurol 5, 525-35 (2006)

  • [4]F Lauretani, M Maggio, C Silvestrini, A Nardelli, M Saccavini, G P Ceda: Parkinson’s disease (PD) in the elderly: an example of geriatric syndrome (GS)? Arch Gerontol Geriatr 54, 242-6 (2012)

  • [5]D A Bennett, L A Beckett, A M Murray, K M Shannon, C G Goetz, D M Pilgrim, D A Evans: Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334, 71-6 (1996)

  • [6]T Buracchio, Z Arvanitakis, S Leurgans, D A Bennett: Parkinsonian signs and incident falls in older persons without Parkinson’s disease. J Am Geriatr Soc 58, 205-6 (2010)

  • [7]D A Fleischman, R S Wilson, J A Schneider, J L Bienias, D A Bennett: Parkinsonian signs and functional disability in old age. Exp Aging Res 33, 59-76 (2007)

  • [8]F Lauretani, G P Ceda, P Pelliccioni, L Ruffini, A Nardelli, A Cherubini, M Maggio: Approaching neurological diseases to reduce mobility limitations in older persons. Curr Pharm Des 20, 3149-64 (2014)

  • [9]J Verghese, C Wang, R B Lipton, R Holtzer: Motoric cognitive risk syndrome and the risk of dementia. JGerontol A Biol Sci Med Sci 68, 412-8 (2013)

  • [10]F Lauretani, G P Ceda, A Nardelli, M Maggio: Should post-mortem brain dissection be performed in Parkinson’s disease with atypical dementia? Aging Clin Exp Res 27, 103-5 (2015)

  • [11]F Lauretani, G P Ceda, M Maggio, A Nardelli, M Saccavini, L Ferrucci: Capturing side-effect of medication to identify persons at risk of delirium. Aging Clin Exp Res 22, 456-8 (2010)

  • [12]J Birks: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Sust Rev 1, CD005593 (2006)

  • [13]T Muyaquil, R Camicioli: Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementias. Dement Geriatr Cogn Dis Extra 2, 546-72 (2012)

  • [14]P N Tariot, M R Farlow, G T Grossberg, S M Graham, S McDonald, I Gergel: Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized, controlled trial. JAMA 291, 317-324 (2004)

  • [15]A P Portsteinsson, G T Grossberg, J Mintzer, J T Olin: Memantine-MEM-MD-12 Study Group: Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomised, double-blind, placebo-controlled trial. Curr Alzheimer Res 5, 83-89 (2008)

  • [16]R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, A Burns, T Dening, D Findlay, C Holmes, A Huges, R Jacoby, R Jones, I McKeith, A Macharouthu, J O’Brien, P Passmore, B Sheehan, E Juszczak, C Katona, R Hills, M Knapp, C Ballard, R Brown, S Banerjee, C Onions, M Griffin, J Adams, R Gray, T Johnson, P Bentham, P Phillips: Donepezil and memantin for moderate-to-severe Alzheimer’s disease. N Engl J Med 366, 893-903 (2012)

  • [17]T Dantoine, S Auricombe, M Sarazin, H Becker, J J Pere, I Burdeix: Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60, 110-118 (2006)

  • [18]J Shua-haim, J Smith, F Picard, G Sedek, S Athalye, F Pommier, G Lefevre: Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by a coadministration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig 28, 361-374 (2008)

  • [19]J T Olin, V Bhatnagar, P Reyes, B Koumaras, X Meng, S Brannan: Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (study ENA713B US32). Int J Geriatr psychiatry 25, 419-426 (2012)

  • [20]M W Riepe, G Adler, B Ibach, B Weinkauf, F Tracik, I Gunay: Domain-specific improvement of cognition on memantin in patients with Alzheimer’s disease treated with rivastigmine. Dement Geriatr Cogn Disord 23, 301-306 (2007)

  • [21]M R Farlow, G Alva, X Meng, J T Olin: A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Res Med Opin 26, 263-269 (2010)

  • [22]S H Choi, K W Park, D L Na, H J Han, E J Kim, Y S Shim, J H Lee, Expect Study Group: Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 27, 1375-1383 (2011)

  • [23]A Atri, L W Shaughnessy, J J Locascio, J H Growdon: Lomg-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22, 209-221 (2008)

  • [24]S Hartmann, HJ Mobius: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 18, 81-85 (2003)

  • [25]O L Lope, J T Becker, A S Wahed, J Saxton, R A Sweet, D A Wolk, W Klunk, ST Dekosky: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 600-607 (2009)

  • [26]L S Schneider, P S Insel, M W Weiner, Alzheimer’s Disease Neuroimaging I: Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Neurol 68, 58-66 (2011)

  • [27]J Wang, J T Yu, H F Wang, X F Meng, C Wang, C C Tan, L Tan: Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 86, 101-9 (2015)

  • [28]J McCleery, D A Cohen, A L Sharpley: Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev 3, CD009178 (2014)

  • [29]R Stowe, N Ives, C E Clarke, K Deane, Van Hilten, K Wheatley, R Gray, K Handley, A Furmston: Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson’s disease patients with motor complications. Cochrane Database Syst Rev 7, CD007166 (2010)

  • [30]R Gray, N Ives, C Rick, S Patel, A Gray, C Jenkinson, E McIntosh, K Wheatley, A Williams, C E Clarke: Long term effectivness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384, 1196-205 (2014)

  • [31]H F Wang, J T Yu, S W Tang, T Jiang, C C Tan, X F Meng, C Wang, M S Tan, L Tan: Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86, 135-43 (2015)

  • [32]I McKeith, T Del Ser, P Spano, M Emre, K Wesnes, R Anand, A Cicin-Sain, R Ferrara: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-6 (2000)

  • [33]D Aarsland, K Laake, J P Larsen, C Lanvin: Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72, 708-12 (2002)

  • [34]M Emre, D Aarsland, A Albanese, E J Byrne, G Deuschl, P P De Deyn, F Durif, J Kulisevsky, T van Laar, A Lees, W Poewe, A Robillard, M M Rosa, E Wolters, P Quarg, S Tekin, R Lane: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351, 2509-18 (2004)

  • [35]I Leroi, J Brandt, S G Reich, C G Lyketsos, S Grill, R Thompson, L Marsh: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 19, 1-8 (2004)

  • [36]B Ravina, M Putt, A Siderowf, J T Farrar, M Gillespie, A Crawley, H H Fernandez, M M Trieschmann, S Reichwein, T Simuni: Donepezil for dementia in Parkinson’s disease: a randomised, double-blind, placebo-controlled, crossover study. J Neurol Neurosurg Psychiatry 76, 934-9 (2005)

  • [37]D Aarsland, C Ballard, Z Walker, F Bostrom, G Alves, K Kossakowski, I Leroi, F Pozo-Rodriguez, L Minthon, E Londos: Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8, 613-18 (2009)

  • [38]I Leroi, R Overshott, E J Byrne, E Daniel, A Burns: Randomised controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 24, 1217-21 (2009)

  • [39]M Emre, M Tsolaki, U Bonuccelli, A Destee, E Tolosa, A Kutzelnigg, A Ceballos-Baumann, S Zdravkovic, A Bladstrom, R Jones, 11018 Study Investigators: Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9, 969-77 (2010)

  • [40]B Dubois, E Tolosa, R Katzenschlager, M Emre, A J Lees, G Schumann, E Pourcher, J Gray, G Thomas, J Swartz, T Hsu, M L Moline: Donepezil in Parkinson’s disease dementia: a randomised, double-blind efficacy and safety study. Mov Disord 27, 1230-8 (2012)

  • [41]E Mori, M Ikeda, K Kosaka: Donepezil for dementia with Lewy bodies: a randomised, placebo-controlled trial. Ann Neurol 72, 41-52 (2012)

  • [42]G Pagano, G Rengo, G Pasqualetti, G D Femminella, F Monzani, N Ferrara, M Tagliati: Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiaty 86, 767-73 (2015)

  • [43]L Morgante, A Epifanio, E Spina, M Zappia, A E Di Rosa, R Marconi, G Basile, G Di Raimondo, P La Spina, A Quattrone: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27, 153-6 (2004)

  • [44]W C Olanow, K Kieburtz, O Rascol, W Poewe, A H Schapira, M Emre, H Nissinen, M Leinonen, F Stocchi, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators: Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28, 1064-71 (2013)

  • [45]T J Moore, J Glenmullen, D R Mattison: Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174, 1930-3 (2014)

  • [46]WJ Jansen, R Ossenkoppele, DL Knol, B M Tijms, P Scheltens, F R Verhey, P J Visser, Amyloid Biomarker Study Group: Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924-38 (2015)

  • [47]A Cherubini, J Oristrell, X Pla, C Ruggiero, R Ferretti, G Diestre, A M Clarfield, P Crome, C Hertogh, V Lesauskaite, GI Prada, K Szczerbinska, E Topinkova, J Sinclair-Cohen, D Edbrooke, GH Mills: The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 171, 550-6 (2011)

  • [48]P Crome, A Cherubini, J Oristrell: The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert Rev Clin Pharmacol 7, 457-68 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Randomized controlled trials for Alzheimer disease and Parkinson disease

Fulvio Lauretani 1,*, Andrea Ticinesi 2,3, Tiziana Meschi 2,3, Giulio Teresi 1, Gian Paolo Ceda 1, Marcello Maggio 1
Affiliations
Article Info

1 Geriatric Clinic and Laboratory of Movement Analysis, Geriatric and Rehabilitation Department, University Hospital of Parma, Via Gramsci 14, I-431126 Parma, Italy

2 Internal Medicine and Critical Subacute Care Unit, Parma University Hospital, Via Gramsci 14, I-431126 Parma, Italy

3 Department of Clinical and Experimental Medicine, University of Parma, Via Gramsci 14, I-431126 Parma, Italy

*Author to whom correspondence should be addressed.

 

Abstract

The continuous increase in elderly and oldest-old population, and subsequent rise in prevalence of chronic neurological diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), are a major challenge for healthcare systems. These two conditions are the most prevalent neurodegenerative diseases in older persons and physicians should engage treatment for these patients. In this field, Randomized Clinical Trials (RCTs) specifically focused on elderly populations are still lacking. The aim of this study was to identify RCTs conducted among AD and PD and to examine the difference between mean age of enrollment and incidence of these two neurodegenerative diseases. We found that the scenario is different between PD and AD. In particular, the enrollment for PD trials seems to include younger persons than AD, although the incidence of both diseases is similar and highest after 80 years old. The consequence of these results could influence conclusive guidelines of treatment in older parkinsonian patients.

Keywords

  • Review
  • Alzheimer’s Diseases
  • Parkinson’s Disease
  • Randomized Clinical Trials
  • Evidence Based Medicine

References